Novocral (Ceftazidime)

Ceftazidime, the active ingredient in Novocral, is a third‑generation cephalosporin presented as an injectable solution for intravenous use. It treats severe Gram‑negative bacterial infections, including those caused by Pseudomonas aeruginosa, in hospitalized patients and other clinical settings. It is also indicated for complicated urinary tract, lower respiratory, and intra‑abdominal infections where potent Gram‑negative coverage is required.

GNH USA supplies Novocral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide with reliable, quality‑assured products.

Ceftazidime is a broad‑spectrum cephalosporin used to treat infections caused by Gram‑negative bacteria.

- Severe Gram‑negative infections: provides bactericidal activity to eradicate the pathogen. - Pseudomonas aeruginosa infections: effective against resistant strains in hospital‑acquired settings. - Complicated urinary tract infections: clears infection when oral agents are insufficient. - Lower respiratory tract infections: treats pneumonia caused by susceptible organisms. - Intra‑abdominal infections: combats mixed bacterial flora in peritonitis and related conditions.

Ceftazidime may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or mild pruritus. - Injection site pain: discomfort at the intravenous access point.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: potentially life‑threatening inflammation of the colon. - Seizures: especially in patients with renal dysfunction or high plasma concentrations.

When using Ceftazidime, clinicians should observe several precautionary measures to ensure safe therapy.

- Renal impairment: adjust dose based on creatinine clearance. - Hypersensitivity: avoid in patients with known cephalosporin or penicillin allergy. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Superinfection: monitor for Clostridioides difficile‑associated diarrhea. - Concomitant nephrotoxic drugs: use with caution when combined with aminoglycosides or loop diuretics. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ceftazidime can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity. - Probenecid: reduces renal clearance, raising ceftazidime levels. - Loop diuretics: may potentiate renal toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception.